胃腺癌中MET的过表达、基因扩增及相关临床病理特征
MET overexpression, gene amplification and relevant clinicopathological features in gastric adenocarcinoma.
作者信息
Zhang Jing, Guo Lei, Liu Xiuyun, Li Wenbin, Ying Jianming
机构信息
Department of Pathology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
出版信息
Oncotarget. 2017 Feb 7;8(6):10264-10273. doi: 10.18632/oncotarget.14382.
This study was conducted to investigate the expression of MET in Chinese gastric adenocarcinoma cohort, the correlation between MET overexpression and clinical pathological features, HER2 expression and MET gene amplification. A total of 816 gastric adenocarcinoma patients were included and MET and HER2 immunohistochemical (IHC) staining were performed. IHC and dual-color silver in situ hybridization analysis were performed in the tissue microarrays, constructed from the 240 patients who were randomly selected. MET overexpression (IHC 3+) was observed in 6.0% (49/816) of the cohort. MET overexpression rate was higher in patients with poor prognostic factors, such as clinical stages III/IV (p =0.012) and pathologic stages T3/T4 (p =0.027). The HER2 overexpression (IHC 3+) rate was 8.8% (72/816) and MET overexpression rate was higher in HER2 positive patients (9.7%, 7/72). A high concordance rate (94.6%) between MET overexpression and gene amplification was demonstrated. Therefore, MET overexpression could serve as a prognostic biomarker and a potential therapeutic target for gastric cancer.
本研究旨在探讨MET在中国胃腺癌队列中的表达情况、MET过表达与临床病理特征之间的相关性、HER2表达以及MET基因扩增情况。共纳入816例胃腺癌患者，并进行了MET和HER2免疫组织化学（IHC）染色。对从随机选取的240例患者构建的组织芯片进行了IHC和双色银原位杂交分析。该队列中6.0%（49/816）的患者观察到MET过表达（IHC 3+）。在具有不良预后因素的患者中，如临床分期III/IV期（p = 0.012）和病理分期T3/T4期（p = 0.027），MET过表达率更高。HER2过表达（IHC 3+）率为8.8%（72/816），且HER2阳性患者的MET过表达率更高（9.7%，7/72）。MET过表达与基因扩增之间显示出较高的一致性率（94.6%）。因此，MET过表达可作为胃癌的预后生物标志物和潜在治疗靶点。
Zotero 插件